166 related articles for article (PubMed ID: 35715547)
1. Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space.
Carcelen AC; Winter AK; Moss WJ; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mwansa FD; Mulenga L; Rhoda DA; Hayford K; Mutembo S
Sci Rep; 2022 Jun; 12(1):10217. PubMed ID: 35715547
[TBL] [Abstract][Full Text] [Related]
2. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
[TBL] [Abstract][Full Text] [Related]
4. Measles immunity gaps among children and adolescents with HIV in Zambia despite high measles vaccination and antiretroviral therapy coverage.
Mutembo S; Yang Y; Carcelen A; Winter AK; Mwansa FD; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mulenga L; Hayford K; Moss WJ
AIDS; 2023 Nov; 37(13):2021-2029. PubMed ID: 37418463
[TBL] [Abstract][Full Text] [Related]
5. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
[TBL] [Abstract][Full Text] [Related]
7. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
8. Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.
Malama K; Tichacek A; Kelly H; Parker R; Inambao M; Sharkey T; Wall KM; Kilembe W; Price MA; Fast P; Priddy F; Allen S
Hum Vaccin Immunother; 2022 Nov; 18(5):2066426. PubMed ID: 35446726
[TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
[TBL] [Abstract][Full Text] [Related]
10. How much does it cost to measure immunity? A costing analysis of a measles and rubella serosurvey in southern Zambia.
Carcelen AC; Hayford K; Moss WJ; Book C; Thuma PE; Mwansa FD; Patenaude B
PLoS One; 2020; 15(10):e0240734. PubMed ID: 33057405
[TBL] [Abstract][Full Text] [Related]
11. Using Locally Derived Seroprevalence Data on Measles, Mumps, Rubella, and Varicella by Birth Cohort to Determine Risks for Vaccine-Preventable Diseases During International Travel.
Rosario-Rosario G; Gareca M; Kincaid H; Knouse MC
J Travel Med; 2015; 22(6):396-402. PubMed ID: 26412393
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012.
Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF
Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751
[TBL] [Abstract][Full Text] [Related]
13. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era.
Mazaba ML; Siziya S; Monze M; Cohen D
BMC Infect Dis; 2020 Feb; 20(1):101. PubMed ID: 32013873
[TBL] [Abstract][Full Text] [Related]
17. Rubella seroprevalence using residual samples from the South African measles surveillance program: a cross-sectional analytic study.
Motaze NV; Makhathini L; Smit SB; Adu-Gyamfi CG; Fortuin M; Wiysonge CS; Suchard SM
Hum Vaccin Immunother; 2020 Nov; 16(11):2656-2662. PubMed ID: 32298204
[No Abstract] [Full Text] [Related]
18. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
Amela C; Pachón I; de Ory F
Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
